Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
Shares of McKesson are down 0.22% at $878.59. The company is worth $102.43B, number 154 out of 300 on our list.
The 52-week range is $722.11 to $996.84. Today's price is about 57% of the way from the low to the high. Holders are ahead 16.0% over twelve months, and up 14.7% across the last three months.
On the chart it holds above both the 50-day ($871.20) and 200-day ($843.71) moving averages; RSI is 56, and the last 30 sessions moved at roughly 27% annualized volatility.
Revenue for the quarter ended Jun 2026 was $105.38B, up 7.7% from a year earlier, with $1.03B of net profit (a 1.1% margin).
Valuation works out to 23.5 times trailing earnings, about in line with its own five-year average of 23.8.
12 analysts follow the stock and the average call is "buy". The mean target, $1,000.73, sits 13.9% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
McKesson distributes drugs and medical supplies, and has a growing oncology and specialty-drug business.
What tends to move it. Specialty drug volume, GLP-1 distribution and pharmacy reimbursement drive results.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -1.8% | Bearish |
| Price vs 50-day average | +0.8% | Bullish |
| Price vs 200-day average | +4.1% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 55.7 | Bullish |
| MACD (12,26,9) | 5.85 | Bearish |
| Bollinger band position | 20% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 1:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q1, ended Jun 2026
Quarter 2027/Q1
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Below its usual level · 38th percentile, 5-year average 23.8x
#1792 of 2974 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 88th percentile, 5-year average -38.7x
Near the top of its 5-year range · 81st percentile, 5-year average 0.2x
#478 of 5140 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$177.79M (1 inflow days, 19 outflow days).
Across the full calendar years shown, the annual payout grew by roughly 11.2% a year.
$878.59 is the latest print for MCK, a move of -0.22% against yesterday's close of $880.50. Today's low and high so far: $877.06 and $896.60.
Equity value comes to $102.43B at the current price. By that measure it is number 154 of the 300 names in our coverage.
Buyers pay 23.5 times the last twelve months of profit (EPS $38.55). Averaged over five years the multiple has been 23.8, and today's level ranks in the 38th percentile of its own history.
The year's floor is $722.11 and the ceiling $996.84. Shares are 11.9% away from that ceiling.
It does. Payouts over the past twelve months work out to a 0.37% yield; the latest ex-dividend date was September 1, 2026.
Of 12 analysts, 83% say buy, 17% hold and 0% sell. Price targets average $1,000.73, with the most cautious at $905.00 and the most optimistic at $1,080.00.
McKesson distributes drugs and medical supplies, and has a growing oncology and specialty-drug business.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.